Mode
Text Size
Log in / Sign up

PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic MedicationsMeals May Not Matter for Most New Heart and Diabetes Pills

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider food effects on absorption for cardiovascular and diabetic medications to optimize adherence.

This PRISMA scoping review analyzed 36 publications to evaluate the impact of food on the oral bioavailability of medications used in patients with cardiovascular disease and diabetes. The scope included clinical pharmacokinetic studies and randomized clinical trials assessing the fasted state versus fed state. Primary outcomes focused on maximum concentration, rate of absorption, and overall drug exposure.

Results demonstrated that food generally reduced maximum concentration and delayed the rate of absorption for several agents. However, there was no significant effect on overall drug exposure for the majority of medications reviewed. Specific recommendations varied; semaglutide is recommended for administration on an empty stomach, while pitavastatin showed higher bioavailability in the fasted state. Conversely, vericiguat and higher doses of rivaroxaban were better absorbed when taken with food.

For patients with swallowing difficulties, the review noted that rivaroxaban, apixaban, and edoxaban may be crushed and administered via nasogastric tube or orally mixed with applesauce. Safety data regarding adverse events were not reported in the included literature. The authors suggest that dosing without strict regard to meals may facilitate patient adherence and contribute to improved therapeutic outcomes.

Limitations were not explicitly detailed in the source material. Clinicians should interpret these findings as a synthesis of existing pharmacokinetic data rather than new clinical trial evidence. Practice relevance centers on balancing bioavailability concerns with practical adherence strategies for complex medication regimens.

Why Meal Timing Confused Patients

Imagine you’re at dinner and your doctor says, “Take your heart pill now.” You wonder: should you swallow it with your steak, or wait until after dessert? For years, patients have juggled pill bottles and meal plans, hoping to get the best effect.

The confusion isn’t accidental. Early drugs often required strict timing because food could either boost or block their action. When a new medication arrives, the label may still list “take with food” or “take on an empty stomach,” even if the real impact is minimal.

The Surprising Flexibility of New Pills

Heart disease and type 2 diabetes affect millions worldwide. In the United States alone, about 1 in 3 adults has high blood pressure, and roughly 10 % live with diabetes. Both conditions need daily medicines that stay in the body long enough to protect the heart and control sugar.

Patients often miss doses because they can’t coordinate pills with meals, especially when schedules are hectic. Missed doses can lead to higher blood pressure, more heart attacks, or worse blood‑sugar control. A simpler dosing routine could improve adherence and outcomes.

The Surprising Flexibility of New Pills

But here’s the twist: a recent scoping review of 36 clinical studies found that most of the newest cardiovascular and antidiabetic drugs work just as well whether you take them with food or on an empty stomach. The only changes observed were lower peak concentrations and a slight delay in how fast the drug entered the bloodstream. Overall exposure—the amount that matters for effectiveness—stayed the same.

How Food Changes Drug Absorption

Think of a drug’s journey like a car entering a busy highway. Food acts like rush‑hour traffic: it slows the car down and may keep it from reaching top speed quickly, but the car still reaches its destination. For most of the drugs reviewed—such as sacubitril/valsartan, most direct oral anticoagulants, and SGLT‑2 inhibitors—food created that traffic jam, lowering the “peak” (the highest concentration) but not reducing the total distance traveled (overall exposure).

Two exceptions behaved differently. Semaglutide, a GLP‑1 receptor agonist, reached its best effect when taken on an empty stomach, much like a car that needs a clear road to speed up. Pitavastatin also showed higher absorption without food. Conversely, vericiguat and higher doses of rivaroxaban performed

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundFood–drug interactions are common in orally administered therapies. In order to achieve optimal therapeutic efficacy and safety, it is important for patients to understand the most appropriate way to take their medications in accordance with their diet.ObjectivesTo evaluate the impact of food on the oral bioavailability of novel cardiovascular and antidiabetic drugs, including sacubitril/valsartan, direct oral anticoagulants, sodium-glucose cotransporter-2 inhibitors, semaglutide, vericiguat, pitavastatin, and bempedoic acid.MethodsPubMed, Scopus, and Cochrane Library databases were searched from inception to May 2024, following the guidelines of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) statement. The search strategy employed keywords including ‘food drug interactions’, ‘food effect’, ‘bioavailability’, and ‘bioequivalence’, combined with the names of the investigated drugs. Eligible publications comprised clinical pharmacokinetic studies and randomized clinical trials evaluating the effect of food on drug bioavailability.ResultsA total of 36 publications met the inclusion criteria. For most drugs, food was found to reduce the maximum concentration and delay the rate of absorption of the active substance without significantly affecting overall drug exposure. Therefore, these drugs can generally be administered regardless of meals. Semaglutide is recommended to be administered on an empty stomach, and pitavastatin demonstrated higher bioavailability in the fasted state. In contrast, vericiguat and higher doses of rivaroxaban are better absorbed when taken with food. For patients with swallowing difficulties, rivaroxaban, apixaban, and edoxaban may be crushed and administered either via a nasogastric tube or orally mixed with applesauce.ConclusionFor a substantial proportion of novel cardiovascular and antidiabetic therapies, dosing without strict regard to meals is supported by available evidence. This level of flexibility may facilitate patient adherence and contribute to improved therapeutic outcomes in clinical practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.